Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GSK: US pharma...

    GSK: US pharma president Jack Bailey to step down in December

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-22T09:15:16+05:30  |  Updated On 17 Aug 2021 11:06 AM IST

    Commenting on his time at GSK, Jack Bailey said, "After more than a decade at GSK and nearly three decades in the life sciences industry, I look forward to the chance to explore my next professional chapter."


    New Delhi: GSK has announced that Jack Bailey, President US Pharmaceuticals has decided to step down from his role at the end of the year. Bailey will be succeeded by Maya Martinez-Davis, currently Regional President, Latin America Region at EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany.


    GSK continues to evolve its business. This includes an expanded pipeline and preparing launches of oncology medicines. Martinez-Davis brings an outstanding experience of successfully bringing new speciality care treatments to patients. She is currently Regional President, Latin America Region and was previously SVP, Global Oncology at EMD Serono (Merck KGaA). Prior to this, she spent thirteen years at Pfizer leading various business units around the world including Oncology and Vaccines.


    Luke Miels, President Global Pharmaceuticals, GSK, said, "Jack is an exceptional leader who has made a very significant contribution to the success of GSK during his decade of leadership in the US."


    "As we continue to grow and reshape our business globally, we are pleased to have found a leader in Maya who will bring a valuable US experience and deep therapy area expertise to expanding our speciality care capabilities and market presence."


    Commenting on his time at GSK, Jack Bailey said, "After more than a decade at GSK and nearly three decades in the life sciences industry, I look forward to the chance to explore my next professional chapter. I am enormously proud of every GSK US colleague who has worked so hard to navigate an exceptionally dynamic operating environment while returning the US Affiliate to double-digit revenue growth these past several years. I am confident the company will build upon the talent, culture and performance success of the US Affiliate as it now expands its portfolio into oncology."


    Martinez-Davis will join GSK in mid-September and will assume responsibility of the US Pharmaceuticals business at GSK on January 1, 2020. Bailey will remain as a strategic consultant to GSK on the US external environment through 2020.


    Read Also: GSK ends Ebola vaccine RnD; transfers license to US institute

    Global PharmaceuticalsGSKGSK businessJack BaileyMartinez Davisleadership changesLuke Mielsoncologyoncology drugspharmapharma companypharma news

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok